Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cells (B7-H3-targeting)
- Development stage
- Unknown
- Lead developer
- Seattle Children's
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal, Intratumoral, Intravenous, Parenteral
01
Overview
CAR-T cells (B7-H3-targeting) refers to chimeric antigen receptor (CAR) T-cell therapies engineered to target B7-H3 (CD276), an immunoregulatory transmembrane glycoprotein overexpressed in various solid tumors and central nervous system (CNS) malignancies. These therapies involve genetically modifying autologous or allogeneic T cells to express a CAR that specifically binds to B7-H3, enabling them to recognize and eliminate B7-H3-expressing cancer cells. B7-H3 is highly expressed in pediatric solid tumors, brain tumors (such as diffuse intrinsic pontine glioma [DIPG], diffuse midline glioma [DMG], and diffuse hemispheric glioma [DHG]), pancreatic cancer, and adrenocortical carcinoma (ACC), while showing limited expression in normal tissues. Multiple clinical trials, such as the BrainChild-03 trial, are evaluating B7-H3-targeting CAR-T cells, demonstrating safety, feasibility, and potential efficacy in early-phase studies.
- Other names
- B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TB7-H3 CAR-T cellsB-7-H3 CAR-T cellsB 7-H3 CAR-T cellsB7-H3-targeted CAR-T cellsB-7-H3-targeted CAR-T cellsB 7-H3-targeted CAR-T cellsB7-H3-targeting CAR-T cellsB-7-H3-targeting CAR-T cellsB 7-H3-targeting CAR-T cellsanti-B7-H3 CAR-T cellsanti-B-7-H3 CAR-T cellsanti-B 7-H3 CAR-T cells
Beyond the preview
Go deeper on CAR-T cells (B7-H3-targeting).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cells (B7-H3-targeting).